DK184890A - USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES - Google Patents

USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES Download PDF

Info

Publication number
DK184890A
DK184890A DK184890A DK184890A DK184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A
Authority
DK
Denmark
Prior art keywords
immunotoxin
auto
cell
preparation
treatment
Prior art date
Application number
DK184890A
Other languages
Danish (da)
Other versions
DK184890D0 (en
Inventor
Patrick J Scannon
Richard C Harmon
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of DK184890D0 publication Critical patent/DK184890D0/en
Publication of DK184890A publication Critical patent/DK184890A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK184890A 1988-02-03 1990-08-02 USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES DK184890A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15174488A 1988-02-03 1988-02-03
PCT/US1989/000440 WO1989006968A1 (en) 1988-02-03 1989-02-03 Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Publications (2)

Publication Number Publication Date
DK184890D0 DK184890D0 (en) 1990-08-02
DK184890A true DK184890A (en) 1990-10-03

Family

ID=22540082

Family Applications (1)

Application Number Title Priority Date Filing Date
DK184890A DK184890A (en) 1988-02-03 1990-08-02 USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES

Country Status (5)

Country Link
EP (1) EP0397798A4 (en)
JP (1) JPH03503887A (en)
AU (1) AU633251B2 (en)
DK (1) DK184890A (en)
WO (1) WO1989006968A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
ES2077670T3 (en) * 1988-12-13 1995-12-01 Univ Florida METHODS AND COMPOSITIONS USED FOR EARLY DETECTION AND TREATMENT OF INSULIN DEPENDENT DIABETES MELLITUS.
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
CA2049007A1 (en) * 1989-03-06 1990-09-07 Michael Daniel Cahalan Assay for and treatment of autoimmune diseases
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (en) * 1991-02-26 1995-02-11 Italfarmaco Spa IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
CA2507749C (en) * 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
EP1015496B1 (en) 1997-03-05 2009-06-17 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Divalent anti-t cells immunotoxins and use thereof
CA2326692C (en) * 1998-04-22 2012-11-13 David M. Neville Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
WO2020247872A1 (en) * 2019-06-05 2020-12-10 Magenta Therapeutics, Inc. T-cell depleting therapies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232447A1 (en) * 1986-02-13 1987-08-19 Xoma Corporation Lectin immunotoxins
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
EP0256471A3 (en) * 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
EP0380542B1 (en) * 1987-08-17 1996-04-24 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Method for treating malignancy and autoimmune disorders in humans
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
JPH03503164A (en) * 1988-02-03 1991-07-18 エクソウマ　コーポレーション Immunosuppression by anti-pan T-cell immunotoxin compositions

Also Published As

Publication number Publication date
WO1989006968A1 (en) 1989-08-10
JPH03503887A (en) 1991-08-29
EP0397798A4 (en) 1991-10-30
DK184890D0 (en) 1990-08-02
AU633251B2 (en) 1993-01-28
EP0397798A1 (en) 1990-11-22
AU3215789A (en) 1989-08-25

Similar Documents

Publication Publication Date Title
DK184890D0 (en) USE OF ANTI-T-CELL-IMMUNOTOXIN FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF AUTO-IMMUNE DISEASES
DK215987A (en) PHARMACEUTICAL PREPARATIONS OF SYRELABLE SUBSTANCES FOR TILORAL ADMINISTRATION
DK362189A (en) PHARMACEUTICAL PREPARATION FOR INTRAVENOES ADMINISTRATION
NO922005D0 (en) PHARMACEUTICAL PREPARATIONS
DK333788A (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF DAMAGED CARTRIC TISSUE
DK149988A (en) STABLE PHARMACEUTICAL PREPARATIONS
DK184087A (en) PHARMACEUTICAL PREPARATIONS WITH IMPROVED BIOTAIL AVAILABILITY
DK413987D0 (en) PHARMACEUTICAL PREPARATIONS
NO872551D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK397388A (en) DERIVATIVES OF N-AMINOBUTYL-N-PHENYLARYLAMIDS FOR THERAPEUTIC USE AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES
DK652787D0 (en) PHARMACEUTICAL PREPARATIONS
DK226488D0 (en) USE OF ACE INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO874200L (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK635988D0 (en) 1,3-BUTANDIOLACETOACETATE DERIVATIVES AND USE OF 1,3-BUTANDIOLACETOACETATE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK447887A (en) PHARMACEUTICAL PREPARATIONS
DK298389A (en) PHARMACEUTICAL PREPARATION FOR TOPICAL USE INCLUDING AN AMINE-FUNCTIONAL MEDICINE
DK0458855T3 (en) Pharmaceutical preparation for the treatment of tonsillitis
NO875359D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO873423D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO872233D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK500589D0 (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF LUNGE OBSTRUCTIONS
DK701588D0 (en) N-HYDROXY-5-PHENYL-2-FURANCARBOXIMIDAMIDES AND ITS USE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO883663D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK149588A (en) XYLOMETAZOLE-CONTAINING PHARMACEUTICAL PREPARATIONS
DK469487A (en) PHARMACEUTICAL TREATMENT MEDICINE

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment